Table 3.
Incidence of WHO Stage 3 and 4 conditions on ART stratified by age group
| All patients | Aged >50 years | Aged 15 to 50 years | Comparison of incidence by age group | ||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
||||
| Condition | Count (%) (n=41,088) | Incidence (per 100 person-years) | Count (%) (n=2591) | Incidence (per 100 person-years) | Count (%) (n=38,497) | Incidence (per 100 person-years) | p-value (>50 vs 15 to 50) |
| Weight loss >10% | 650 (1.6) | 1.77 | 53 (2.1) | 1.11 | 597 (1.6) | 0.66 | <0.01 |
| Diarrhoea, unexplained | 510 (1.2) | 1.51 | 48 (1.9) | 1.00 | 462 (1.2) | 0.51 | <0.01 |
| Fever, unexplained | 356 (0.9) | 0.90 | 26 (1.0) | 0.54 | 330 (0.9) | 0.36 | 0.05 |
| Oral candidiasis | 1752 (4.3) | 5.12 | 161 (6.2) | 3.37 | 1591 (4.1) | 1.75 | <0.01 |
| Pulmonary TB | 2304 (5.6) | 6.05 | 177 (6.8) | 3.70 | 2127 (5.5) | 2.35 | <0.01 |
| Bacterial pneumonia | 434 (1.1) | 1.17 | 35 (1.4) | 0.73 | 399 (1.0) | 0.44 | <0.01 |
| Bacterial infections, severe, including pneumonia | 368 (0.9) | 0.98 | 29 (1.1) | 0.61 | 339 (0.9) | 0.37 | <0.01 |
| Oral hairy leukoplakia | 1268 (3.1) | 2.69 | 65 (1.3) | 1.36 | 1203 (3.1) | 1.33 | 0.85 |
| Lymph node TB | 58 (0.1) | 0.10 | 2 (0.1) | 0.04 | 56 (0.2) | 0.06 | 0.68 |
| Overall Stage 3 | 7954 (19.4) | 20.90 | 612 (23.6) | 12.80 | 7342 (19.1) | 8.10 | <0.01 |
| Wasting syndrome by HIV/stunting/severe malnutrition | 339 (0.8) | 0.90 | 27 (1.0) | 0.56 | 312 (0.8) | 0.34 | 0.01 |
| Cryptococcosis extrapulmonary | 322 (0.8) | 0.65 | 15 (0.6) | 0.31 | 307 (0.8) | 0.34 | 0.77 |
| Pneumocystis pneumonia | 328 (0.8) | 0.62 | 13 (0.5) | 0.27 | 315 (0.8) | 0.35 | 0.78 |
| Toxoplasmosis of the brain | 421 (1.0) | 0.88 | 21 (0.8) | 0.44 | 400 (1.0) | 0.44 | 0.98 |
| Penicillium marneffei infection | 90 (0.2) | 0.16 | 3 (0.1) | 0.06 | 87 (0.2) | 0.10 | 0.47 |
| Candidiasis oesophagus/trachea/bronchi/lungs | 453 (1.1) | 1.08 | 29 (1.1) | 0.61 | 424 (1.1) | 0.47 | 0.18 |
| Extrapulmonary TB | 1886 (4.6) | 3.51 | 72 (2.8) | 1.51 | 1814 (3.1) | 2.00 | 0.02 |
| Lymphoma | 14 (0.0) | 0.02 | 0 (0.0) | 0 | 14 (0.0) | 0.02 | 0.39 |
| Herpes simplex infection | 238 (0.6) | 0.50 | 13 (0.5) | 0.27 | 225 (0.6) | 0.23 | 0.75 |
| Non-TB mycobacteria infection | 826 (2.0) | 1.64 | 37 (1.4) | 0.77 | 791 (2.1) | 0.87 | 0.47 |
| Mycosis disseminated | 289 (0.7) | 0.63 | 16 (0.6) | 0.33 | 273 (0.7) | 0.30 | 0.68 |
| Kaposi's sarcoma | 236 (0.6) | 0.55 | 15 (0.6) | 0.31 | 221 (0.6) | 0.24 | 0.34 |
| Cytomegalovirus infection | 187 (0.5) | 0.44 | 12 (0.5) | 0.25 | 175 (0.5) | 0.19 | 0.38 |
| Overall Stage 4 | 5762 (14.0) | 11.88 | 279 (10.8) | 5.83 | 5483 (14.2) | 6.05 | 0.52 |
ART, antiretroviral therapy; TB, tuberculosis. Values in bold values indicate those that reached statistical significance (p<0.05).